Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids
Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by high drug resistance and poor prognosis. Novel therapeutic and stratification strategies are urgently needed. Here, we present an integration of in-depth genomic and transcriptomic characterization with drug screening and clinical outcome based on a catalogue of 51 patient-derived tumor organoids (PDOs) from resected PDAC. Known PDAC molecular subtypes and their prognostic value are conserved in organoids. Integration of transcriptomic and drug response profiles suggest a metabolism-mediated modulations of drug resistance. Copy number alterations on chromosome 13q and wild-type status of TP53 emerged as potential novel genomic biomarkers for sensitivity to 5-FU and oxaliplatin treatment, respectively. Functional testing of targeted drugs in PDOs revealed its additional value for genome-driven personalized oncology. Co-deletion of TP53/POLR2A increased vulnerability to RNA polymerase II inhibition, pointing to a promising target for personalized treatment in PDAC.Significance Patient-derived PDAC organoids hold great promise as surrogate tumor models for personalized oncology. By integrating highly granular molecular, drug sensitivity and clinical data, we demonstrate that PDOs are valid models for molecular characterization and response prediction that also enable identification of novel drug sensitivity biomarkers and resistance mechanisms in PDAC..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 30. Aug. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Le Blanc, Solange [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.08.26.457743 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032469268 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032469268 | ||
| 003 | DE-627 | ||
| 005 | 20230429093223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210829s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.08.26.457743 |2 doi | |
| 035 | |a (DE-627)XBI032469268 | ||
| 035 | |a (biorXiv)10.1101/2021.08.26.457743 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Le Blanc, Solange |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by high drug resistance and poor prognosis. Novel therapeutic and stratification strategies are urgently needed. Here, we present an integration of in-depth genomic and transcriptomic characterization with drug screening and clinical outcome based on a catalogue of 51 patient-derived tumor organoids (PDOs) from resected PDAC. Known PDAC molecular subtypes and their prognostic value are conserved in organoids. Integration of transcriptomic and drug response profiles suggest a metabolism-mediated modulations of drug resistance. Copy number alterations on chromosome 13q and wild-type status of TP53 emerged as potential novel genomic biomarkers for sensitivity to 5-FU and oxaliplatin treatment, respectively. Functional testing of targeted drugs in PDOs revealed its additional value for genome-driven personalized oncology. Co-deletion of TP53/POLR2A increased vulnerability to RNA polymerase II inhibition, pointing to a promising target for personalized treatment in PDAC.Significance Patient-derived PDAC organoids hold great promise as surrogate tumor models for personalized oncology. By integrating highly granular molecular, drug sensitivity and clinical data, we demonstrate that PDOs are valid models for molecular characterization and response prediction that also enable identification of novel drug sensitivity biomarkers and resistance mechanisms in PDAC. | ||
| 700 | 1 | |a Ishaque, Naveed |e verfasserin |4 aut | |
| 700 | 1 | |a Jabs, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Schuth, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Debnath, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Ten, Foo Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Leonhardt, Carl-Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a König, Anna-Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Bieg, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Eckert, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Gaida, Matthias M. |e verfasserin |4 aut | |
| 700 | 1 | |a Volkmar, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Schenk, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Offringa, Rienk |e verfasserin |4 aut | |
| 700 | 1 | |a Giese, Nathalia A. |e verfasserin |4 aut | |
| 700 | 1 | |a Schlesner, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Büchler, Markus W. |e verfasserin |4 aut | |
| 700 | 1 | |a Eils, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Strobel, Oliver |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 30. Aug. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.08.26.457743 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 08 | ||
| 953 | |2 045F |a 570 | ||